BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Sarah-Jane Dawson, Nikitsa Makretsov, Fiona Blows, Kristy Driver, Elena Provenzano, John Le Quesne, Laura Baglietto, Gianluca Severi, Graham Giles, Catriona Ann McLean, Grace Callagy, Andrew Green, Ian Ellis, Karen Gelmon, Gulisa Turashvili, S Leung, S Aparcio, David Huntsman, Carlos Caldas, Paul Pharoah

Research output: Contribution to journalArticleResearchpeer-review

187 Citations (Scopus)

Abstract

Five studies of 11 212 women with early-stage breast cancer were analysed. Individual patient data included tumour size, grade, lymph node status, endocrine therapy, chemotherapy and mortality. BCL2, ER, progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) levels were determined in all tumours. A Cox model incorporating the time-dependent effects of each variable was used to explore the prognostic significance of BCL2.
Original languageEnglish
Pages (from-to)668 - 675
Number of pages8
JournalBritish Journal of Cancer
Volume103
Issue number5
DOIs
Publication statusPublished - 2010

Cite this